Overview

A Study to Assess the Effect of Verinurad on the Electric Activity of the Heart

Status:
Completed
Trial end date:
2020-08-21
Target enrollment:
Participant gender:
Summary
This study will be conducted to investigate the safety of verinurad in healthy volunteers in combination with allopurinol 300 mg, compared with placebo in particular its effect on electrocardiogram (ECG), with focus on the QT/QTc interval
Phase:
Phase 1
Details
Lead Sponsor:
AstraZeneca
Collaborator:
Parexel
Treatments:
Allopurinol
Verinurad